The interplay of metabolically associated fatty liver disease and carbohydrate metabolism disorders: Current understanding of pathogenesis and treatment
Authors:
- Almazov National Medical Research CentreACAlmazov National Medical Research Centre
- A.A. MikhailovaAMA.A. Mikhailova
- K.A. PogosianKPK.A. Pogosian
- K.A. GolovatyukKGK.A. Golovatyuk
- О. С. ФуксОФО. С. Фукс
- Т. Л. КароноваТКТ. Л. Каронова
Open Access
- 1 January 2024
- journal article
- Published by Focus Endocrinology in FOCUS. Endocrinology
- Vol. 5 (3) , 64-71
Abstract
Metabolic-associated fatty liver disease (MAFLD) is a chronic, non-infectious condition associated with metabolic disorders, including type 2 diabetes mellitus. This review describes current understanding of the MAFLD pathogenesis and its relationship to impaired carbohydrate metabolism, particularly the role of insulin resistance, dysregulated autophagy, and other factors contributing to disease development. Furthermore, it analyzes existing therapeutic approaches to MAFLD management, including the use of ursodeoxycholic acid as an autophagy modulator, as well as various glucose-lowering medications, such as glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, and thiazolidinediones. Additionally, the pathogenetic role of fibroblast growth factor-21 in MAFLD development and the potential clinical application of FGF-21-based therapies are described. Thus, this overview reflects current knowledge regarding the pathogenesis and treatment of MAFLD, highlighting the necessity of a comprehensive approach to managing this condition in the context of its strong association with impaired carbohydrate metabolismKeywords
This publication has 31 references indexed in Scilit:
- Autophagy alterations in obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease: the evidence from human studiesInternal and Emergency Medicine, 2024
- New approaches to triglyceride reduction: Is there any hope left?American Journal of Preventive Cardiology, 2024
- The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative reviewEuropean Journal of Clinical Pharmacology, 2023
- Effects of high-fat diet-induced diabetes on autophagy in the murine liver: A systematic review and meta-analysisLife Sciences, 2022
- Regulation of autophagy by bile acids and in cholestasis - CholestoPHAGY or CholeSTOPagyBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2021
- Ursodeoxycholic acid alleviates nonalcoholic fatty liver disease by inhibiting apoptosis and improving autophagy via activating AMPKBiochemical and Biophysical Research Communications, 2020
- From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment optionsJHEP Reports, 2019
- A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?Acta Diabetologica, 2018
- Effect of ursodeoxycholic acid on glycemic markers: A systematic review and meta-analysis of clinical trialsPharmacological Research, 2018
- Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient dietBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2015